KRIBIOLISA™ Relatlimab ELISA

Introduction:

Relatlimab is a monoclonal antibody designed for the treatment of melanoma. Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor. It is used in combination with nivolumab to treat melanoma. It is under development by Bristol-Myers Squibb. It is made using Chinese hamster ovary cells. The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March 2022.

Intended Use:

The KRIBIOLISA™ Relatlimab ELISA is used as an analytical tool for quantitative determination of Relatlimab in human serum and plasma.

Principle:

The method employs the quantitative sandwich enzyme immunoassay technique. LAG3 recombinant proteins are pre-coated onto microwells. Samples and standards are pipetted into microwells and Anti-Human LAG3 (Relatlimab) present in the sample are bound by the capture antibody. Then, an HRP (horseradish peroxidase) conjugated anti-Human IgG antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Relatlimab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.